A Phase 2 interventional study of Catumaxomab 100µg and Catumaxomab 140µg in Patients With Gastric Peritoneal Carcinomatosis, sponsored by Gustave Roussy, Cancer Campus, Grand Paris. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-26.
Sponsored by Gustave Roussy, Cancer Campus, Grand Paris · Phase 2, Interventional, and Treatment
Treatment by association of complete surgical excision of the lesions and intraperitoneal immunotherapy using Catumaxomab for patients with gastric peritoneal carcinomatosis
6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.
This study's enrollment of 26 is below the median of 45 across 5,170 interventional studies indexed under Carcinoma.
Browse Carcinoma studies →Gustave Roussy, Cancer Campus, Grand Paris is the lead sponsor of 242 studies on the registry; 65 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Inclusion Criteria (intraoperative):
Exclusion Criteria:
Exclusion Criteria (intraoperative):
* D0 : 20 μg of catumaxomab * D2 : 40 μg * D4 : 80 μg
Drug: Catumaxomab 140µg
* D0 : 10 μg of catumaxomab * D2 : 30 μg * D4 : 60 μg
Drug: Catumaxomab 100µg
Progression Free Survival
Time frame: every 3 months for the first two years
Progression Free Survival
Time frame: every 3 months for the first two years then every 4 months on year 3 then every 6 months on year 4 and 5
This study is terminated, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gustave Roussy, Cancer Campus, Grand Paris